Notable Calls

RSS feed
Notablecalls@gmail.com

Monday, October 27, 2008

 

Thoratec (NASDAQ:THOR): Buy aggressively on any weakness in the stock. $31 target. - Canaccord

Canaccord is out with a very strong defense on Thoratec (NASDAQ:THOR) following a medical device correction (MDC) notifying physicians the percutaneous lead in HM-II may malfunction over time via
wear.

Action. *Buy aggressively on any weakness in the stock. $31 target.

*NOT a recall...clearing the air. *Released Friday post-close, this report has been broadly mistaken as an HM-II recall; which it is NOT. It is instead a notification mandated by FDA making physicians/patients aware the lead, which connects the pump with the external controller, may suffer “wear and fatigue [that] may result in damage that could interrupt pump function, require re-operation to replace the pump and potentially… serious injury or death.” There were only 27 lead failures in 1,972 HM-II implants over five years (five deaths; none caused by the lead).

*Is this “significant” to docs? Will it impact uptake? *After speaking over the weekend with several LVAD surgeons, Canaccord's key takeaways are: 1) every physician said the notice is NOT new news to clinicians, thus would not impact practice patterns at all; if anything they were surprised by the “low” incidence rate (27/1,972); 2) HM-II improves patients’ health so much their activity level increases dramatically (e.g., driving a Harley to work) which increases wear on the lead; 3) these patients are sick and have NO other options; as such lead fatigue is the least of their worries; 4) all of the investigators agreed this issue would have NO impact on the DT trial outcome.

*Weekend due diligence turned out quite bullish – think upside is possible to Q3 (report Thursday), Q4 and 2009 estimates. *Not only did clinicians quell initial concerns that this may adversely impact HM-II uptake, but our surgeon calls also suggested adoption by both transplant and non-transplant hospitals continues at a strong clip.

Notablecalls: Bounce candidate for sure. BofA is also out in defense. Could hit $20 level in a jiffy

PS: Lazard on THOR: Firm notes THOR fell ~50% after hours and they believe it is possible it could fall further on Monday as they believe the current market is not very comfortable with risk."

Comments:
Thoratec posts better than expected3Q profit on heart device sales:

http://biz.yahoo.com/ap/081031/earns_thoratec.html?.v=1
 
Post a Comment



<< Home

Archives

June 2006   July 2006   August 2006   September 2006   October 2006   November 2006   December 2006   January 2007   February 2007   March 2007   April 2007   May 2007   June 2007   July 2007   August 2007   September 2007   October 2007   November 2007   December 2007   January 2008   February 2008   March 2008   April 2008   May 2008   June 2008   July 2008   August 2008   September 2008   October 2008   November 2008   December 2008   January 2009   February 2009   March 2009   April 2009   May 2009   June 2009   July 2009  

This page is powered by Blogger. Isn't yours?